18th Oct 2016 07:45
LONDON (Alliance News) - Pharmaceuticals and healthcare services company Clinigen Group PLC on Tuesday said it has opened a new office in Tokyo to expand its presence in Asia.
As part of the launch, Clinigen said it will transfer the marketing authorisation for its Foscavir drug back from Nobel Pharma on November 1. Nobel has been the distribution partner for Foscavir in Japan since 2011.
Foscavir is used to treat cytomegalovirus retinitis in AIDS patients.
"We are focused on building our market leadership positions by expanding in key geographic regions to drive sustained organic growth and better address unmet patient needs for access to critical medicines," said Clinigen Chief Executive Shaun Chilton.
"The opening of our Japanese business helps support our goals and will enable us to effectively serve the Japanese market by supplying our own products, beginning with Foscavir," he added.
Shares in Clinigen were up 0.2% to 751.50 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L